Kanji Meguro
Takeda Pharmaceutical Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kanji Meguro.
Heterocycles | 1990
Masahiro Kajino; Kanji Meguro
A one-step synthesis of new pyrido [2,3-d] pyrimidine derivatives (III) was achieved through the Hantzsch synthesis using 6-aminouracils (I) as enamine nucleophiles
Journal of Medicinal Chemistry | 2009
Shirou Maeda; Toshiko Kita; Kanji Meguro
A series of novel 4,6-di(substituted)amino-1,2-dihydro-1,3,5-triazine derivatives designed to have ClogP of 5.1-7.5 was synthesized and evaluated for their antiseptic properties by MIC and MBC tests against Gram-positive and Gram-negative bacteria, including MRSA, VRE, and P. aeruginosa. Among these compounds, 4-alkyl-6-aralkyl derivatives having ClogP of 6.6-7.1 and 4-alkyl-6-aryl or 4,6-dialkyl derivatives with ClogP of 6.0-6.4 showed pronounced antibacterial activities in both tests.
European Journal of Pharmacology | 1986
Hitoshi Ikeda; Kozo Shimakawa; Go Kito; Kanji Meguro; Takao Matsuo
The antiobesity effects of (S)-(+)-1-(4-chlorophenylthiomethyl)-N-methylethylamine fumarate (AO-124) were examined in rats and dogs. AO-124 suppressed food intake dose dependently in normal, Zucker fatty and VMH-obese rats, and beagle dogs. Its anorectic activity was not altered by pretreatment with methysergide, a serotonin receptor blocker. AO-124 also reduced the hyperphagia induced by 2-deoxy-D-glucose but not that induced by insulin, noradrenaline or muscimol, suggesting that the anoretic mechanism of AO-124 may be implicated in a glucostatic regulatory system of feeding. In addition, AO-124 decreased insulin secretion in response to an oral, but not an intravenous, glucose load. Such a suppression in insulin secretion may be explained by slow absorption of glucose from the intestine: AO-124 delayed the gastric emptying time of glucose and inhibited the active transport of glucose as observed in the everted small intestine. Two week administration of AO-124 to Zucker fatty rats resulted in a significant reduction of plasma insulin levels, body weight gain, and body lipid without exerting any changes in body protein. These findings indicate that AO-124 may be useful as an antibesity agent on the basis of its unique mechanisms of action.
Chemical & Pharmaceutical Bulletin | 1991
Yu Momose; Kanji Meguro; Hitoshi Ikeda; Chitoshi Hatanaka; Satoru Oi; Takashi Sohda
Archive | 1986
Kanji Meguro; Takeshi Fujita
Archive | 1985
Kanji Meguro; Takeshi Fujita
Chemical & Pharmaceutical Bulletin | 1985
Kanji Meguro; Masahiro Aizawa; Takashi Sohda; Yutaka Kawamatsu; Akinobu Nagaoka
Archive | 1986
Kanji Meguro; Takeshi Fujita
Journal of Medicinal Chemistry | 1992
Takashi Sohda; Katsutoshi Mizuno; Yu Momose; Hitoshi Ikeda; Takeshi Fujita; Kanji Meguro
Archive | 1990
Kanji Meguro; Hitoshi Ikeda